Cellect Biotechnology Ltd. (NASDAQ:APOP)

Cellect Biotechnology Ltd. (NASDAQ:APOP) Succeeds In Trial

Cellect Biotechnology Ltd. (NASDAQ:APOP)

Shares of Cellect Biotechnology Ltd. (NASDAQ:APOP) gained 10.8% after the stem cell developer achieved a major milestone with the conclusion a large study on the use of ApoGraft on stem cells derived from fat tissues. According to the company, the technology led to both an expansion of cells and an improvement in unique cell activity and attributes.

Cellect Biotechnology Ltd. (NASDAQ:APOP)

ApoGraft Study Results

According to Cellect Biotechnology Ltd. (NASDAQ:APOP) CEO, Dr. Shai Yarkoni, the study validates the use of the stem cell selection technology on a much wider array of companies and medical centers around the world. The technology could be of great help to the aesthetic and orthopedic industries where fat-derived stem cells are the main raw materials. Up until now, ApoGraft has mostly been used on blood cells. Buoyed by the positive results, Cellect Biotechnology plans to carry out clinical programs and licensing deals for the technology.

APOP Investor Reaction

The positive ApGraft study results helped strengthen investor confidence on the stock seen by the stock skyrocketing to $10 before it dropped to end Wednesday’s trading session at $8.82 a share. The stock is still in consolidation mode after failing on three attempts to rise above the $11 level.

However, the stock is up by more than 140% for the year as it continues to outperform the overall industry. Analysts and brokerage firms have already reacted to the positive trial results by initiating coverage of the stock.

HC Wainwright’s analyst Ram Selvaraju has initiated coverage of the stock with a ‘Buy’ rating. The analysts currently has a $14 price target on Cellect Biotechnology Ltd. (NASDAQ:APOP).

Strategic Alliances

Renewed investor interest on the stock comes on Cellect Biotechnology Ltd. – American Depositary Shares (NASDAQ:APOP) announcing that the significant milestone with ApoGraft technology, positions the company to pursue strategic alliances with other companies.

“This breakthrough finding is increasing our addressable market by an order of magnitude. We can now actively seek strategic alliances for the commercialization of ApoGraft™” in aesthetic medicine as well as orthopedic indications,” said Mr. Yarkoni.

Separately, Cellect Biotechnology Ltd. (NASDAQ:APOP) has confirmed the appointment of Dr. Ronit Bakimer-Kleiner as the new Chief Development Officer, replacing Dr. Yaron Pereg. She takes over with over twenty years of experience as a scientist and executive manager in the biotechnological industrial environment. Ronit previously served as the General Manager of Cognate Bioservices Ltd.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $APOP and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Roka Bioscience Inc (NASDAQ:ROKA)

Roka Bioscience Inc (NASDAQ:ROKA) Catches Market by Surprise

Roka Bioscience Inc (NASDAQ:ROKA)

Roka Bioscience Inc (NASDAQ:ROKA) shares are up almost 50%, to $0.53, on heavy volume despite the lack of any publicly available news that could account for such extreme price action. The company’s last press release was in August of 2017.

Roka Bioscience Inc (NASDAQ:ROKA)

Roka Bioscience Inc (NASDAQ:ROKA) is a molecular diagnostics company that develops, markets, and sells advanced testing solutions for the food safety testing market. Their lead product is the Atlas® Detection Assay that integrates proprietary technologies into their Atlas System which automates all aspects of the diagnostic testing on a single, integrated platform. The Atlas System and Detection Assays are designed to provide customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies.

Roka Bioscience Asset Sale

In August, Roka Bioscience Inc (NASDAQ:ROKA) announced that it entered into an asset purchase agreement with Rokabio, Inc., a wholly-owned subsidiary of Institute for Environmental Health, Inc., for the sale of substantially all of the assets of Roka Bioscience in an all-cash transaction for an aggregate purchase price of $17.5 million. Shares lost 9% the day the asset sale was announced and have been in a downward trajectory until a few days ago when shares gapped up and briefly traded about the psychologically important $2.50 level.

ROKA Stock Performance

The market capitalization of Roka Bioscience Inc (NASDAQ:ROKA) is less than $7 million with a float of 4.33 million shares. Investors have not had a good year. Year to date, ROKA shares have lost around 75% and, prior to today, lost over 34%. Reports have analyst’s consensus, one year price target at $10.

Sales have been improving every year. In 2012, the company reported just $100,000 in sales but that number improved each year and, in 2016, the company posted $7.2 million in sales. However, the upward momentum has not been seen in earnings. For 2016 the company reported a per share loss of (-$17.42), which was better than the loss of (-$21.18) reported in 2015, and the per share loss of (-$29.30) reported in 2014.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ROKA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Viking Therapeutics Inc. (NASDAQ:VKTX)

Viking Therapeutics Inc. (NASDAQ:VKTX)’s VK2809 Succeeds in Trial

Viking Therapeutics Inc. (NASDAQ:VKTX)

Viking Therapeutics Inc. (NASDAQ:VKTX) fell 5.36% after announcing positive results from an eight-week study of VK2809 as a novel treatment for a wide range of lipid disorders. Study results demonstrate lipid-lowering effects of the small molecule thyroid receptor, as well as anti-fibrotic benefits.

Viking Therapeutics Inc. (NASDAQ:VKTX)

VK2809 vs. Lipid Disorders

Treatment with VK2809 shows statistically significant reductions in liver triglycerides, liver cholesterol, and total lipids in treated animals, relative to vehicle controls. The trials also showed significant changes in expression of key genes associated with non-alcoholic Steatohepatitis development and progression.

“The observed changes in gene expression are exciting, as they corroborate the histologic improvements and suggest potential benefits of insulin sensitivity and metabolic control. VK2809’s therapeutic and safety profile continue to suggest a promising potential role in settings such as NASH and hyperlipidemia,” said CEO, Brian Lian.

Viking Therapeutics Inc. (NASDAQ:VKTX) is trading in an uptrend despite the 5% drop. The stock is up by more than 100% for the year and outperforming the overall industry. Renewed investor interest follows positive clinical trials of the company’s lead program VK2809 and VK0214.

According to Viking Therapeutics Inc. (NASDAQ:VKTX), VK2809 was well tolerated with no significant changes to liver functions it to test subjects relative to controls. VK2809 is a small molecule thyroid receptor that promises therapeutic potential in a range of lipid disorders.

Clinical data has already demonstrated that treatment with VK2809 could lead to a significant reduction in plasma triglycerides as well as LDL Cholesterol in subjects with mild hypercholesterolemia. Viking Therapeutics is currently evaluating it in a randomized, double-blind, placebo-controlled parallels group Phase 2 study.

VK0214 Development

In addition to VK2809, Viking Therapeutics Inc. (NASDAQ:VKTX) is also evaluating VK0214 on the treatment of X-linked adrenoleukodystrophy. The U.S. Food and Drug Administration has already granted the thyroid receptor beta Orphan Drug status.

Study results from a 25-week proof-of-concept study showed VK0214 led to statistically significant reductions in Plasma levels of very long chain fatty acids in treated animals. The therapy also demonstrated reductions in long chain fatty acids in tissues such as in the liver, brain, and spinal cord.

“The impressive effects on plasma VLCFAs strengthen our belief that activation of the thyroid beta receptor can lead to improved lipid processing. The reduction in tissue VLCFAs is particularly exciting, as it suggests a potential direct benefit on tissue-related toxicities,” said Brian Lian, Ph.D., chief executive officer of Viking.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $VKTX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Pluristem Therapeutics Inc. (NASDAQ:PSTI),

Patent Pushes Pluristem Therapeutics Inc. (NASDAQ:PSTI) Higher

Pluristem Therapeutics Inc. (NASDAQ:PSTI)

Pluristem Therapeutics Inc. (NASDAQ:PSTI), headquartered in Israel, established a new 52-week high today of $2.02 after the company announced that the European Patent Office has issued the company a patent titled, “Methods for Treating Radiation or Chemical Injury” for its PLX-R18 cell therapy. Volume for the biotechnology stock, up 9% in today’s trading, was heavy – over five times the daily average traded.

Pluristem Therapeutics Inc. (NASDAQ:PSTI),

Pluristem Patent

PLX-R18 is designed to treat bone marrow that is unable to produce enough blood cells due to a variety of causes, including acute radiation syndrome (ARS), certain cancers or cancer treatments, or immune-mediated bone marrow failure. Pluristem Therapeutics Inc. (NASDAQ:PSTI) currently holds several patents worldwide to cover placental 3D-expanded cells in the treatment of impaired hematopoietic systems when a bone marrow, cord blood, or peripheral blood transplant takes place.

Yaky Yanay, Co-CEO and President of Pluristem Therapeutics Inc. (NASDAQ:PSTI) stated “PLX-R18 cells have shown the ability to trigger regeneration of the hematopoietic system, thereby supporting the recovery and production of white blood cells, red blood cells and platelets. With its capabilities, we believe that PLX-R18 has the potential to treat a broad range of hematologic indications, which together constitute a substantial global market.”

PSTI Stock Performance

Three investment firms follow Pluristem Therapeutics Inc. (NASDAQ:PSTI) and all three rate PSTI shares as a “Strong Buy”. Their consensus, one year price target is $3.50. Investors have been hot on the stock. Over the past year PSTI stock is up over 30% and is up over 60% for the quarter. That upward momentum has resulted in a Relative Strength Index figure of 73 – prior to today’s trading. Traders believe that a figure above 70 represents an “overbought” condition.

Pluristem Therapeutics Inc. (NASDAQ:PSTI) reported no sales for FY2017 after posting $2.8 million in 2016. The per share loss for FY2017 was (-$0.32) which followed a loss of (-$0.29) in 2016. Of note is a consistent expansion of the number of outstanding shares. For 2013, 55.48 million shares were outstanding. The dilutive expansion of the number of shares has increased every year and for 2017 the figure stands at 87.43 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PSTI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Strata Skin Sciences, Inc. (NASDAQ:SSKN) Rebounding

Strata Skin Sciences, Inc. (NASDAQ:SSKN)

Strata Skin Sciences, Inc. (NASDAQ:SSKN) stock is up over 20% today after a week that has seen the Skin Science company lose over 30% of its value. SSKN stock is experiencing heavy volume during this rebound as more than two million shares have traded hands for a stock that has an average daily volume of less than 200,000.

Strata Skin Sciences, Inc. (NASDAQ:SSKN)

Strata Skin Sciences

Strata Skin Sciences, Inc. (NASDAQ:SSKN), headquartered in Horsham, PA, is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® laser and VTRAC® excimer lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions; the STRATAPEN™ MicroSystem, marketed specifically for the intended use of micropigmentation; and Nordlys, a multi-technology aesthetic laser device.

SSKN Stock Review

Interestingly, the current market price for SSKN shares is below published figures of the company’s cash per share which is posted at $1.51. It has a book to share ratio of $4.99.

Yesterday SSKN shares hit a new 52-week low – hitting $1.10. Their 52-week high of $5.40 was achieved last April and the shares spiked again in May though not enough to establish a new high.

Sales have been increasing at a rapid pace. In 2014, Strata Skin Sciences, Inc. (NASDAQ:SSKN) reported sales at $900,000 but that number increased the following year and also in 2016 when the company posted a figure of $31.8 million. However losses have plagued the shareholders over the past five years. Last year’s per share loss of (-$1.57) was, by far, the smallest in the company’s history and could serve as a signal that the company has turned the corner.

One must always be on the lookout for equity diluting events when it comes to biotech firms and Strata Skin Sciences, Inc. (NASDAQ:SSKN) is no exception. In 2012 there were 620,000 shares outstanding. That number has increased every year and for 2016 was listed at 2.12 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SSKN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Pain Therapeutics, Inc. (NASDAQ:PTIE)

Pain Therapeutics, Inc. (NASDAQ:PTIE) Announces Positive Results

Pain Therapeutics, Inc. (NASDAQ:PTIE)

Austin, TX-based Pain Therapeutics, Inc. (NASDAQ:PTIE) shares are up over 35% in mid-day trading after the firm announced the completion of a Phase I clinical study for PTI-125, a new experimental drug therapy to treat Alzheimer’s Disease. By 1PM, PTIE shares had a volume of over 16.7 million for a stock that has an average daily trading volume of less than 40,000 shares.

Pain Therapeutics, Inc. (NASDAQ:PTIE)

Remi Barbier, President & CEO of Pain Therapeutics, Inc. (NASDAQ:PTIE) stated “The clinical data are encouraging. Given the absence of dose-limiting effects in healthy adults, an excellent non-clinical safety database, a strong scientific rationale, and multiple peer-reviewed publications and research grant awards, we are eager to move this drug program to the next level of development.”

Study Results

Pain Therapeutics conducted this study with support from a $1.7 million research grant award from the National Institute on Aging, part of the National Institutes of Health.

PTI-125 was evaluated, at a single U.S. site, in 24 healthy human volunteers for safety, tolerability, and pharmacokinetics. The drug was well-tolerated in all subjects.  Importantly, PTI-125 showed no treatment-related adverse effects and no dose-limiting safety findings.  Pharmacokinetic measurements showed PTI-125, a small molecule, was rapidly absorbed.  Dose-proportionality outcomes were observed over the entire dose range of 50 to 200 mg.  Pain Therapeutics Inc. (NASDAQ”PTIE) scientists plan to present full results of this study at the 10th Annual International Conference on Clinical Trials on Alzheimer’s Disease (CTAD), in Boston, MA, on November 1-4th.

PTIE Stock Performance

Pain Therapeutics, Inc. (NASDAQ:PTIE) is a nano-cap company and has a market capitalization less than $30 million. The biotechnology company has been without sales for the last three years and, accordingly, has posted per share losses over that time period (-$1.92), (-$2.16), and for 2016 (-$2.26). On a positive note, the number of outstanding shares has not materially increased over the past five years so equity dilution has been of little concern.

 

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PTIE and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Evoke Pharma Inc. (NASDAQ:EVOK) To Submit NDA Application

Evoke Pharma Inc. (NASDAQ:EVOK)

Evoke Pharma Inc. (NASDAQ:EVOK) traded lower after announcing positive top-line results from a comparative exposure pharmacokinetic (PK) study. Shares of the specialty pharmaceutical company fell 6.98% to end Monday’s trading session at $3.20 a share.

Evoke Pharma Inc. (NASDAQ:EVOK)

New Drug Application

The sell-off added fuel to a downtrend that has plagued the stock in recent trading sessions. Evoke Pharma Inc. (NASDAQ:EVOK) has struggled to close above the $4 a share mark on two attempts amidst concerns that an uptrend, which began in August, could be losing momentum. However, the stock has outperformed the overall industry and is up by more than 40% for the year.

The stock is currently rated as a “Strong Buy” by one analyst firm, a “Hold” by three firms, and a “Sell” by one firm, according to data compiled by Zack Investment research

The topline clinical results come from a trial that sought to demonstrate that the company’s proposed novel treatment for diabetic gastroparesis has similar systemic exposure to Reglan Tablets. Buoyed by the positive results, the company intends to submit a New Drug Application (NDA) with a selected dose of Gimoti to the U.S. Food and Drug Administration (FDA). Gimoti is Evoke Pharma Inc. (NASDAQ:EVOK) lead candidate drug for the treatment of symptoms associated with acute and recurrent diabetic gastroparesis. Last month, the company completed subject dosing as part of an ongoing pharmacokinetic study. Results are expected in the fourth quarter.

The company is preparing the NDA application in partnership with RHO, a well-established research organization that that has worked on other successful gastrointestinal NDA submissions

“In the first quarter of 2018, we will submit the NDA with these PK data, as well as safety and efficacy data from five prior Evoke clinical studies in healthy volunteers and patients with diabetic gastroparesis. We believe Gimoti has the potential to become the new standard of care for patients suffering from this debilitating disease,” said CEO David Gonyer.

Q2 Financial Results

Separately, Evoke Pharmaceuticals reported a net loss of (-$1.6) million for the second quarter, nearly half a net loss of (-$3) million reported last year. Net loss in the quarter was partially offset by $1.3 million associated with a change in the fair value of warrant liability.

Research and development expenses in the quarter came in at $2 million compared to $2.1 million reported in Q2, 2016. Evoke Pharma Inc. (NASDAQ:EVOK) had approximately $12.6 million in cash and cash equivalent as of June 30, 2017.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $EVOK and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

OncoSec Medical Inc. (NASDAQ:ONCS) Falls After Pricing Offering

OncoSec Medical Inc. (NASDAQ:ONCS)

OncoSec Medical Inc. (NASDAQ:ONCS) shares fell 12.9% after the biotechnology company announced it has entered into a definitive purchase agreement with accredited investors. Pursuant to the agreement, the company is to issue 5.3 million shares of common stock at $1.34 a share.

OncoSec Medical Inc. (NASDAQ:ONCS)

Public Offering

The company has also agreed to issue the investors unregistered warrants, expiring in 5.5 years, for the purchase of up to 3.9 million shares of common stock at $1.25 a share. OncoSec Medical expects gross proceeds of $7.1 million from the offering.

OncoSec Medical Inc. (NASDAQ:ONCS) expects net proceeds of approximately $6.2 million after the deduction of fees and other expenses. The offering should close on or about October 25, 2017.

Net proceeds from the offering are to be used for working capital, general corporate purposes, and for ongoing clinical research and development programs. The pricing of the purchase agreement appears to have spooked investors as seen by the stock’s failure to rise above $1.30.

Prior to the announcement of the offering, OncoSec Medical Inc. (NASDAQ:ONCS) had been on an impressive run after a string of positive clinical trial results. However, the uptrend appears to be losing momentum – threatening to push the stock to multi-year lows.

Clinical Trials

OncoSec has been trading higher in the market following the presentation of positive Phase 2 data for it lead candidate drug ImmunoPulse IL-12 for the treatment of metastatic melanoma. Phase 2 study results indicate that only 10% of the patients treated with the drug in combination with pembrolizumab experienced serious adverse events

Preliminary trial results also indicate that ImmunoPulse IL-12 has the potential to trigger key immunologic events.

“Collectively, these study findings reinforce the combination of ImmunoPulse IL-12 and pembrolizumab to address a significant unmet medical need in melanoma patients who are unlikely to respond to anti-PD-1 therapies,” said Punit Dhillon, CEO, and President of OncoSec.

OncoSec Medical Inc. (NASDAQ:ONCS) is to present additional data in ongoing Phase 2 combination study at the upcoming Society for Immunotherapy of Cancer Annual Meeting.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ONCS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Atossa Genetics Inc (NASDAQ:ATOS)

Atossa Genetics Inc (NASDAQ:ATOS) Continuing Upward Move

Atossa Genetics Inc (NASDAQ:ATOS)

Atossa Genetics Inc (NASDAQ:ATOS) stock fell on the open then rallied on heavy volume to finish the day with a 29% gain – closing at $0.62. ATOS shareholders have seen the stock move up by 24% for the week on the back of a company announcement that the Ernest Mario School of Pharmacy at Rutgers, The State University at New Jersey, plans to conduct a study utilizing Atossa’s intraductal microcatheter technology. Atossa Genetics is a clinical-stage drug company developing novel, proprietary therapeutics and delivery methods for breast cancer and other breast conditions.

Atossa Genetics Inc (NASDAQ:ATOS)

Rutgers Study

The Rutgers program is in the research and development phase and has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory body. Studies demonstrating safety and efficacy, among other things, and regulatory approvals will be required before commercialization. The Rutgers researchers believe that directly administering drugs into the breast duct where breast cancer grows, by inserting microcatheters into the nipple, is a better alternative than systemic administration, because the drugs will be directly delivered to the tissue. The Rutgers program uses a unique directed delivery system comprised of nanoscale pharmaceutical carriers loaded with single drugs.

Steven Quay, MD, PhD, Atossa CEO and President of Atossa Genetics Inc (NASDAQ:ATOS) stated in a press release “We are encouraged that a leading research institution like Rutgers recognizes the potential merit of our microcatheter technology. Atossa fully supports additional research utilizing our patented microcatheter technology,”.

ATOS Stock Performance

Although down over 65% for the year, in the past quarter ATOS shareholder have seen their stock gain over 60%. Currently ATOS stock is about double its 52-week low of $0.32 but still far from its 52-week high of $2.60.

Atossa Genetics Inc (NASDAQ:ATOS) has posted no sales over the past three years. On the plus side, it has seen shrinking losses over the past four years and in 2016 reported a per share loss of (-$2.16). However ATOS shareholders should be aware that the number of outstanding shares has increased every year – resulting in shareholder’s equity being diluted. According to reports, ATOS has a consensus 1-year price target among analysts of $26.25.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ATOS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Kalvista Pharmaceuticals Inc (NASDAQ:KALV)

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) Stock Making New Run

Kalvista Pharmaceuticals Inc (NASDAQ:KALV)

Shares of Kalvista Pharmaceuticals Inc (NASDAQ:KALV) have rallied two days in a row on heavy volume two weeks after reaching a new 52-week high on news of a collaboration with Merck. On October 10, 2017 Kalvista announced Merck acquired around a 10% stake for a payment of $9.1 million. That news sent the shares rocketing over 38% and establishing a new 52-week high at $15.80, but profit-takers stepped in and the shares closed just over $10. Shares traded sideways over the next eight trading days, then yesterday shares spiked again and then gapped up to open today before hitting an inter-day high of $14.46, and closing at $13.02.

Kalvista Pharmaceuticals Inc (NASDAQ:KALV)

Deal Terms

The collaboration between Merck and Kalvista Pharmaceuticals Inc (NASDAQ:KALV) for KVD001, the Kalvista’s investigational intravitreal injection candidate currently in development for potential treatment of diabetic macular edema (DME), as well as future oral DME compounds based upon plasma kallikrein inhibition. Under the terms of the agreement, KalVista has granted to Merck certain rights including an option to acquire KVD001 through a period following completion of the Phase 2 proof-of-concept trial that KalVista intends to commence later this year. Kalvista Pharmaceuticals Inc (NASDAQ:KALV) has also granted to Merck a similar option to acquire investigational orally delivered molecules for DME that KalVista will continue to develop as part of its ongoing research and development activities.

KALV Stock Review

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) shareholders have had a good year and seen their shares appreciate by over 67% and over the past month KALV shares have gone up by over 62%. Kalvista reported no sales in 2015 or 2016 but for FY2017 they posted $1.5 million in sales. Their performance also jumped in the per share P&L. In 2016, the company posted its largest per share loss ever (-$18.23) but they shrank that number to a loss of (-$4.00) for FY2017. KALV shares have a Relative Strength Index figure of 79 – well into the “overbought” range.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $KALV and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.